Press releases
- ASCO Data Highlights NeXT Personal® Ultra-sensitive MRD Performance in Early-stage Breast Cancer Recurrence Detection and Immunotherapy Monitoring
- Personalis Announces Start of Cancer MRD Testing Commercialization Collaboration with Tempus
- Personalis Announces Podium Presentations and Abstracts Accepted at ASCO 2024
- Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Personalis Reports First Quarter 2024 Financial Results
- Personalis to Announce First Quarter 2024 Financial Results
- Personalis to Present at the 23rd Annual Needham Virtual Healthcare Conference
- Data Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting
- Personalis Announces Publication Validating NeXT Personal® Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring
More ▼
Key statistics
As of last trade, Personalis Inc (04X:BER) traded at 1.25, 47.50% above the 52 week low of 0.8495 set on Nov 10, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.26 |
---|---|
High | 1.26 |
Low | 1.25 |
Bid | 1.16 |
Offer | 1.35 |
Previous close | 1.25 |
Average volume | 2.47k |
---|---|
Shares outstanding | 51.94m |
Free float | 51.53m |
P/E (TTM) | -- |
Market cap | 76.35m USD |
EPS (TTM) | -1.89 USD |
Data delayed at least 15 minutes, as of Jun 10 2024 11:22 BST.
More ▼